Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02715258
Other study ID # THR-1442-C-450
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 2016
Est. completion date April 2017

Study information

Verified date June 2021
Source Theracos
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).


Description:

This was a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of once daily oral administration of bexagliflozin tablets, 20 mg or placebo tablets, in male and female subjects with T2DM who were treatment-naïve or previously treated with 1 oral hypoglycemic agent (OHA). Prospective subjects being treated with one OHA were eligible if they had an HbA1c between 6.5% and 10.0% and were willing to complete a 6-week washout. Individuals taking thiazolidinediones were not eligible for the study. All eligible subjects were to start a 2-week placebo run-in period. Subjects who missed no more than 1 dose of the run-in medication, had fasting blood glucose values ≥ 250 mg/dL on no more than two consecutive days, and had an HbA1c level between 7.0% and 10.5% and a fasting glucose level < 250 mg/dL after the run-in period were eligible for randomization. Two hundred and ten (210) subjects were planned to be randomly assigned to receive oral bexagliflozin tablets, 20 mg or placebo, in a 2:1 ratio once daily for 24 weeks. Subjects with uncontrolled hyperglycemia based on blood glucose levels could receive additional approved anti-diabetic medications. Treatment group assignment at the start of the treatment period was stratified by baseline HbA1c level and background anti-diabetes treatment status (treatment naïve or not). Each subject was contacted by telephone at week 2 and was instructed to return to the clinic at weeks 6, 12, 18, and 24 for efficacy assessment and safety monitoring. Subjects returned to the clinic for a follow-up visit at week 26 or 2 weeks after the last dose of investigational product if the subject terminated prior to week 24.


Recruitment information / eligibility

Status Completed
Enrollment 210
Est. completion date April 2017
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility The study population included: 1. Male or female adult subjects = 18 years of age at screening 2. Subjects who were treatment naïve or receiving 1 OHA in combination with diet and exercise 3. Subjects with a diagnosis of T2DM 4. Subjects with HbA1c levels at screening between 7.0% and 10.5% (inclusive) if treatment-naïve or with HbA1c levels between 6.5 and 10.0% (inclusive) if on 1 oral anti diabetic agent 5. Subjects with a BMI = 45 kg/m2 6. Subjects whose doses of medications for hypertension or hyperlipidemia (if applicable) had not changed for at least 30 days prior to screening 7. Subjects who were willing and able to return for all clinic visits and to complete all study required procedures 8. Female subjects of childbearing potential who were willing to use an adequate method of contraception and not become pregnant for the duration of the study. 9. Subjects who maintained glycemic control throughout washout, if applicable. 10. Subjects who had HbA1c levels between 7.0 and 10.5% prior to randomization 11. Subjects who had been compliant in investigational product administration by missing no more than 1 dose of run-in medication Subjects who met any of the following criteria were excluded from the study: 1. A diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young 2. Use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor agonist therapy) or thiazolidinedione class drugs at the time of screening 3. Female subjects who were pregnant or breastfeeding 4. Hemoglobinopathy or carrier status for hemoglobin alleles that affected HbA1c measurement 5. Genitourinary tract infection (e.g., UTI, GMI, vaginitis, balanitis) within 6 weeks of screening or history of = 3 genitourinary infections requiring treatment within 6 months from screening 6. Estimated glomerular filtration rate (eGFR), as calculated by the modification of diet in renal disease study equation (MDRD), < 60 mL/min/1.73 m2 at screening 7. Uncontrolled hypertension defined as a sitting systolic blood pressure >160 mm Hg or diastolic blood pressure > 95 mm Hg at screening 8. A positive result for hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) 9. History of alcohol or illicit drug abuse in the past 2 years 10. Known human immunodeficiency virus (HIV) positive based on medical history 11. Life expectancy < 2 years 12. New York Heart Association (NYHA) Class IV heart failure within 3 months of screening 13. MI, unstable angina, stroke, or hospitalization for heart failure within 3 months of screening 14. Treatment with an investigational drug within 30 days or within 7 half-lives of the investigational drug, whichever was longer 15. Previous treatment with bexagliflozin or EGT0001474 16. Use of any SGLT2 inhibitors, either at the time of screening or in the prior 3 months 17. Currently participating in another interventional trial 18. Not able to comply with the study scheduled visits 19. Any condition, disease, disorder, or clinically relevant abnormality that, in the opinion of the primary investigator, would jeopardize the subject's appropriate participation in this study or obscure the effects of treatment 20. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 2.5 x ULN or total bilirubin = 1.5 x upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome at screening 21. Two or more consecutive FPG measures = 250 mg/dL (13.9 mmol/L) prior to randomization or severe clinical signs or symptoms of hyperglycemia during the washout or run-in periods, including weight loss, blurred vision, increased thirst, or increased urination, or fatigue 22. At last visit prior to randomization, FPG level = 250 mg/dL 23. Prior renal transplantation or evidence of nephrotic syndrome (defined as a urine albumin-to-creatinine ratio (UACR) > 2000 mg/g at screening).

Study Design


Intervention

Drug:
Bexagliflozin
tablets containing 20 mg bexagliflozin
Placebo
tablets matching the appearance of bexagliflozin tablets

Locations

Country Name City State
Canada Research Site Newmarket Ontario
Canada Research Site Pointe-Claire Quebec
Canada Research Site 1 Toronto Ontario
Canada Research Site 2 Toronto Ontario
Canada Research Site Vancouver British Columbia
United States Research Site Calabash North Carolina
United States Research Site Canoga Park California
United States Research Site Chino California
United States Research Site DeSoto Texas
United States Research Site Fort Lauderdale Florida
United States Research Site Fort Worth Texas
United States Research Site Hialeah Florida
United States Research Site Huntington Park California
United States Research Site Los Angeles California
United States Research Site Miami Lakes Florida
United States Research Site Morehead City North Carolina
United States Research Site Munroe Falls Ohio
United States Research Site North Myrtle Beach South Carolina
United States Research Site Orlando Florida
United States Research Site Port Orange Florida
United States Research Site Portland Oregon
United States Research Site San Diego California
United States Research Site Trenton New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Theracos

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Change From Baseline in Fasting Plasma Glucose (FPG) Over Time The fasting plasma glucose (FPG) is measured at each study visit. The subject must have fasted for approximately 10 hours prior to the blood draw to ensure that the FPG value is truly a fasting sample. 24 weeks
Other Change From Baseline of HbA1c From Baseline Over Time Glycated hemoglobin A1c (%) was measured using an HPLC method in the laboratories that had completed NGSP Level I laboratory certification and were traceable to the Diabetes Control and Complications Trial (DCCT) reference method. 24 weeks
Other Proportion of Subjects Who Achieve an HbA1c < 7% Glycated hemoglobin A1c (%) was measured using an HPLC method in the laboratories that had completed NGSP Level I laboratory certification and were traceable to the Diabetes Control and Complications Trial (DCCT) reference method. Up to 24 weeks
Primary Change in HbA1c From Baseline at Week 24 Glycated hemoglobin A1c (%) was measured using an HPLC method in the laboratories that had completed NGSP Level I laboratory certification and were traceable to the Diabetes Control and Complications Trial (DCCT) reference method. 24 weeks
Secondary Change in Systolic Blood Pressure (SBP) From Baseline at Week 24 Blood pressure (BP) measurements are obtained using a calibrated sphygmomanometer in sitting, supine and standing positions. The left arm and same cuff sizes should be used for each measurement at all visits. If the left arm cannot be used at the screening visit or during the study for BP measurements, the reason should be documented and the right arm should be used for BP measurements for all subsequent visits. 24 weeks
Secondary Change in Body Weight From Baseline at Week 24 in Subjects With a BMI = 25 Kg/m2 The body weight was obtained using a calibrated scale as part of complete physical examination or abbreviated physical examination. 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02226003 - Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) Phase 3